Why Infinity Pharmaceuticals Stock Fell Roughly 38%; Here are 79…

Why Infinity Pharmaceuticals Stock Fell Roughly 38%; Here are 79…

Facebook
Twitter
LinkedIn

winner

  • Opiant Pharmaceuticals, Inc. OPNT Shares are up 113.8% to trade at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash plus contingent stock rights (CVRs) of up to $8.00 per share.
  • Freight Technologies, Inc. FRGT Shares rose 113.6% to close at $0.4410 on Monday after analysts at Chardan Capital began coverage of the stock with a price target of $2.25.
  • ToughBuilt Industries, Inc. TBLT Shares gained 72.3% to close at $3.79 after the company reported better-than-expected Q3 EPS results.
  • Exela Technologies, Inc. XELA surged 45.6% to close at $0.4048.
  • Porch Group, Inc. PRCH rose 37.3% to close at $1.40. The company recently reported an unexpectedly large quarterly loss.
  • Mercurity Fintech Holding Inc. MFH gained 36.1% to close at $0.7358.
  • Clovis Oncology, Inc. CLVS surged 32.6% to close at $0.3846. Clovis Oncology recently warned of possible bankruptcy due to liquidity concerns.
  • Getty Images Holdings, Inc. GETY up 31.3% to close at $6.97 after the company reported worse-than-expected Q3 results.
  • Cabaletta Bio, Inc. CABA rose 30.7% to close at $3.11. Cabaletta Bio recently posted a Q3 loss of $0.39 per share.
  • MINISO Group Holding Limited MNSO Soared 29% to close at $9.12 after the company reported better-than-expected first-quarter financial results.
  • Metamaterials Inc. MMAT rose 29% to close at $1.69.
  • Yiren Digital Ltd. YRD gained 27.7% to close at $1.29.
  • Insignia Systems, Inc. ISIG rose 27.7% to close at $8.34. Insignia Systems recently reported earnings per share of $6.57 for the third quarter.
  • Siyata Mobile Inc. SYTA up 26.9% to close at $0.1650, possibly on continued strength after Zacks Small-Cap Research set a $2.50 price target on the stock.
  • PDS Biotechnology Corporation PDSB up 26.1% to $7.06 after the company announced a 100% clinical response in cervical cancer patients in preliminary data from the Phase 2 clinical trial IMMUNOCERV. The company also reported better-than-expected Q3 EPS…

[ad_2]

Source story

More to explorer